Perspectives: Other ErbB2-targeted therapies

Breast Care

Volumn 5, Issue SUPPL. 1, 2010, Pages 25-27

  Nitz, Ulrike ^a  

^a Evangelisches Bethesda Krankenhaus   (Germany)

Author keywords

ErB2 antibody drug conjugate therapy; ErbB dimerization inhibitor; Multifunctional tyrosine kinase inhibitors; Neratinib; Pertuzumab; Trastuzumab DM 1

Indexed keywords

4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; CAPECITABINE; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; MAYTANSINE; MONOCLONAL ANTIBODY; PERTUZUMAB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; TRASTUZUMAB DM 1 CONJUGATE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADVANCED CANCER; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CARDIOTOXICITY; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; FATIGUE; HEADACHE; HUMAN; HYPOKALEMIA; LOADING DRUG DOSE; NAUSEA; NEUROPATHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; RECOMMENDED DRUG DOSE; SHORT SURVEY; SIDE EFFECT; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; VOMITING;

EID: 77952792422     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000285779     Document Type: Short Survey

References (10)

1. Sequist L: Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall cell lung cancer. Oncologist 2007;3:325-330.
2. Rabindran SK, Discafani CM, Rosfjord EC, et al.: Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 2004;64:3958-3965.
3. Burstein HJ, Sun Y, Tan AR, et al.: Neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor: phase 2 results in patients with advanced HER2+ breast cancer. 31st Annual San Antonio Breast Cancer Symposium 2008;abstr 37.
4. Agus DB, Akita RW, Fox WD, et al.: Targeting ligand- activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002;2:127-137.
5. Baselga J, Imadalou K, Paton V, Gray D, Swain S: Efficacy, safety and tolerability of dual monoclonal antibody therapy with pertuzumab + trastuzumab in HER2+ metastatic breast cancer patients previously treated with trastuzumab. Annual San Antonio Breast Cancer Symposium 2008;poster 3138.
6. Gelmon K, Furnoleau P, Verma S, Wardley A, et al.: Results of a phase II trial of trastuzumab and pertuzumab in patients with HER2 positive metastatic breast cancer who had progressed during trastuzumab therapy. J Clin Oncol 2008; 26(suppl):abstr 1026.
7. Lewis Phillips GD, Li G, Dugger DL, et al.: Targeting HER2-positive breast cancer with trastuzumab- DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008;68:9280-9290.
8. Chari RV, Martell BA, Gross JL, et al.: Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res 1992;52:127-131.
9. Beeram M, Burris H, Modi S, Birkner M, et al.: A phase I study of trastuzumab-DM-1, a first in class HER2 antibody-drug conjugate, in patients with advanced HER2+ breast cancer. ASCO Ann Meet Proc (post-meeting ed), J Clin Oncol 2007; 25(suppl):1042.
10. Vukelja S, Rugo H, Vogel C, et al.: A phase II study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer. San Antonio Breast Cancer Symposium 2008;abstr 33.